With the advent of targeted therapy for the treatment of metastatic renal cancer, the routine use of cytoreductive nephrectomy has been questioned. However, available data suggest that cytoreductive nephrectomy remains an integral part of treatment in properly selected patients. This review details the rationale for the continued use of cytoreductive nephrectomy in acceptable surgical candidates in the era of targeted therapy.
Written by:
Crispen PL, Blute ML. Are you the author?
Department of Surgery, University of Kentucky, 800 Rose Street, MS235, Lexington, KY, 40513, USA.
Reference: Curr Urol Rep. 2012 Feb;13(1):38-46.
doi: 10.1007/s11934-011-0225-x
PubMed Abstract
PMID: 22105577
UroToday.com Renal Cancer Section
